The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome

Breast Cancer Research

Volumn 10, Issue 2, 2008, Pages

  Butt, Alison J ^a,b   Sergio, C Marcelo ^a   Inman, Claire K ^a   Anderson, Luke R ^a   McNeil, Catriona M ^a   Russell, Amanda J ^a   Nousch, Marco ^c   Preiss, Thomas ^c   Biankin, Andrew V ^a,b   Sutherland, Robert L ^a,b   Musgrove, Elizabeth A ^a,b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c VICTOR CHANG CARDIAC RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; HEPATITIS B SURFACE ANTIGEN; HSPC111 PROTEIN, HUMAN; MESSENGER RNA; MYC PROTEIN; PRESURFACE PROTEIN 2, HEPATITIS B SURFACE ANTIGEN; PROTEIN; PROTEIN PRECURSOR; SMALL INTERFERING RNA;

ADULT; AGED; ARTICLE; BREAST TUMOR; CELL CYCLE S PHASE; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOBLOTTING; METABOLISM; MIDDLE AGED; MORTALITY; ONCOGENE MYC; POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR CELL LINE; UPREGULATION;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESTROGENS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, MYC; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNOBLOTTING; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROTEIN PRECURSORS; PROTEINS; PROTO-ONCOGENE PROTEINS C-MYC; RNA, MESSENGER; RNA, SMALL INTERFERING; S PHASE; SURVIVAL ANALYSIS; UP-REGULATION;

EID: 48949119505     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr1985     Document Type: Article

References (52)

1. Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer. J Natl Cancer Inst 1998, 90:814-823.
2. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006, 354:270-282.
3. Sutherland RL, Hall RE, Taylor IW. Cell proliferation kinetics of MCF-7 human mammary carcinoma cells in culture and effects of tamoxifen on exponentially growing and plateau-phase cells. Cancer Res 1983, 43:3998-4006.
4. Taylor IW, Hodson PJ, Green MD, Sutherland RL. Effects of tamoxifen on cell cycle progression of synchronous MCF-7 human mammary carcinoma cells. Cancer Res 1983, 43:4007-4010.
5. Osborne CK, Boldt DH, Clark GM, Trent JM. Effects of tamoxifen on human breast cancer cell cycle kinetics: accumulation of cells in early G1 phase. Cancer Res 1983, 43:3583-3585.
6. Prall OWJ, Sarcevic B, Musgrove EA, Watts CK, Sutherland RL. Estrogen-induced activation of cdk4 and cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-cdk2. J Biol Chem 1997, 272:10882-10894.
7. Foster JS, Henley DC, Ahamed S, Wimalasena J. Estrogens and cell-cycle regulation in breast cancer. Trends Endocrinol Metab 2001, 12:320-327.
8. Butt AJ, McNeil CM, Musgrove EA, Sutherland RL. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr-Rel Cancer 2005, 12:S47-S59.
9. Pedram A, Razandi M, Aitkenhead M, Hughes CCW, Levin ER. Integration of the non-genomic and genomic actions of estrogen. J Biol Chem 2002, 277:50768-50775.
10. Dubik D, Shiu RP. Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 1988, 263:12705-12708.
11. Hanson KD, Shichiri M, Follansbee MR, Sedivy JM. Effects of c-myc expression on cell cycle progression. Mol Cell Biol 1994, 14:5748-5755. 359100, 8065309.
12. Prall OWJ, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-cdk2 activation and cell cycle reentry. Mol Cell Biol 1998, 18:4499-4508. 109035, 9671459.
13. Rudolph B, Saffrich R, Zwicker J, Henglein B, Muller R, Ansorge W, Eilers M. Activation of cyclin-dependent kinases by Myc mediates induction of cyclin A, but not apoptosis. EMBO J 1996, 15:3065-3076. 450247, 8670807.
14. Watson PH, Pon RT, Shiu RP. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 1991, 51:3996-4000.
15. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 1987, 328:445-449.
16. Stewart TA, Pattengale PK, Leder P. Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 1984, 38:627-637.
17. Venditti M, Iwasiow B, Orr FW, Shiu RP. C-myc gene expression alone is sufficient to confer resistance to antiestrogen in human breast cancer cells. Int J Cancer 2002, 99:35-42.
18. Mukherjee S, Conrad SE. C-Myc suppresses p21WAF1/CIP1 expression during estrogen signaling and antiestrogen resistance in human breast cancer cells. J Biol Chem 2005, 280:17617-17625.
19. Hui R, Cornish AL, McClelland RA, Robertson JF, Blamey RW, Musgrove EA, Nicholson RI, Sutherland RL. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Clin Cancer Res 1996, 2:923-928.
20. Strezoska Z, Pestov DG, Lau LF. Bop1 is a mouse WD40 repeat nucleolar protein involved in 28S and 5. 8S RRNA processing and 60S ribosome biogenesis. Mol Cell Biol 2000, 20:5516-5528. 86002, 10891491.
21. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005, 102:13550-13555. 1197273, 16141321.
22. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
23. Robustness, Scalability, and Integration of a Wound-Reponse Gene Expression Signature in Predicting Breast Cancer Survival. , http://microarray-pubs.stanford.edu/wound_NKI/explore.html
24. Biankin AV, Morey AL, Lee C-S, Kench JG, Biankin SA, Head DR, Hugh TB, Sutherland RL, Henshall SM. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma. J Clin Oncol 2002, 20:4531-4542.
25. Smyth GK. Limma: linear models for microarray data. Bioinformatics and Computational Biology Solutions Using R and Bioconductor 2005, 397-420. New York, NY: Springer, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W.
26. Scherl A, Coute Y, Deon C, Calle A, Kindbeiter K, Sanchez J-C, Greco A, Hochstrasser D, Diaz J-J. Functional proteomic analysis of human nucleolus. Mol Biol Cell 2002, 13:4100-4109. 133617, 12429849.
27. Andersen JS, Lam YW, Leung AK, Ong SE, Lyon CE, Lamond AI, Mann M. Nucleolar proteome dynamics. Nature 2005, 433:77-83.
28. Grisendi S, Mecucci C, Falini B, Pandolfi PP. Nucleophosmin and cancer. Nat Rev Cancer 2006, 6:493-505.
29. Lam YW, Trinkle-Mulcahy L, Lamond AI. The nucleolus. J Cell Sci 2005, 118:1335-1337.
30. Leary DJ, Huang S. Regulation of ribosome biogenesis within the nucleolus. FEBS Lett 2001, 509:145-150.
31. Oncomine Research™. , http://www.oncomine.org
32. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004, 6:1-6. 1635162, 15068665.
33. Henshall SM, Afar DEH, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, Sutherland RL. Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 2003, 63:4196-4203.
34. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, Edwards LS, Vanden Bergh PM, Hacker NF, Sutherland RL, O'Brien PM. Overexpression of the cell adhesion molecules DDR1, claudin 3 and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004, 10:4427-4436.
35. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, Gish K, Kwok K, Hanna W, Zubovits J, Armes J, Venter D, Hakimi J, Shortreed J, Donovan M, Parrington M, Dunn P, Oomen R, Tartaglia J, Berinstein NL. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci USA 2005, 102:11005-11010. 1182410, 16043716.
36. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD, Livingston DM, Ganesan S. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006, 9:121-132.
37. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, Montgomery K, Ferrari M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani R, Botstein D, Brown PO, Brooks JD, Pollack JR. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004, 101:811-816. 321763, 14711987.
38. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, Smith D, Hartmann L, Fishman D, Berchuck A, Schmandt R, Whitaker R, Gershenson DM, Mills GB, Bast RC. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 2004, 10:3291-3300.
39. Korkola JE, Houldsworth J, Chadalavada RSV, Olshen AB, Dobrzynski D, Reuter VE, Bosl GJ, Chaganti RSK. Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo differentiation of human male germ cell tumors. Cancer Res 2006, 66:820-827.
40. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, Van De Rijn M, Botstein D, Brown PO. Gene expression patterns in human liver cancers. Mol Biol Cell 2002, 13:1929-1939. 117615, 12058060.
41. Graudens E, Boulanger V, Mollard C, Mariage-Samson R, Barlet X, Gremy G, Couillault C, Lajemi M, Piatier-Tonneau D, Zaborski P, Eveno E, Auffray C, Imbeaud S. Deciphering cellular states of innate tumor drug responses. Genome Biol 2006, 7:R19. 1557757, 16542501.
42. Ishikawa M, Yoshida K, Yamashita Y, Ota J, Takada S, Kisanuki H, Koinuma K, Choi YL, Kaneda R, Iwao T, Tamada K, Sugano K, Mano H. Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. Cancer Sci 2005, 96:387-393.
43. Schoenenberger CA, Andres AC, Groner B, van der Valk M, Lemeur M, Gerlinger P. Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription. EMBO J 1988, 7:169-175. 454240, 2834201.
44. Lin CY, Ström A, Vega VB, Kong SL, Yeo AL, Thomsen JS, Chan WC, Doray B, Bangarusamy DK, Ramasamy A, Vergara LA, Tang S, Chong A, Bajic VB, Miller LD, Gustafsson JA, Liu ET. Discovery of estrogen receptor α target genes and response elements in breast tumor cells. Genome Biol 2004, 5:R66. 522873, 15345050.
45. Schlosser I, Holzel M, Murnseer M, Burtscher H, Weidle UH, Eick D. A role for c-Myc in the regulation of ribosomal RNA processing. Nucleic Acids Res 2003, 31:6148-6156. 275450, 14576301.
46. Leung AK, Trinkle-Mulcahy L, Lam YW, Andersen JS, Mann M, Lamond AI. NOPdb: Nucleolar Proteome Database. Nucleic Acids Res 2006, 34:D218-220. 1347367, 16381850.
47. Oskarsson T, Trumpp A. The Myc trilogy: lord of RNA polymerases. Nat Cell Biol 2005, 7:215-217.
48. Strezoska Z, Pestov DG, Lau LF. Functional inactivation of the mouse nucleolar protein Bop1 inhibits multiple steps in pre-rRNA processing and blocks cell cycle progression. J Biol Chem 2002, 277:29617-29625.
49. Hölzel M, Rohrmoser M, Schlee M, Grimm T, Harasim T, Malamoussi A, Gruber-Eber A, Kremmer E, Hiddemann W, Bornkamm GW, Eick D. Mammalian WDR12 is novel member of the Pes-1-Bop1 complex and is required for ribosome biogenesis and cell proliferation. J Cell Biol 2005, 170:367-378. 2171466, 16043514.
50. Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW, Eick D, Kohlhuber F. Control of cell growth by c-Myc in the absence of cell division. Curr Biol 1999, 9:1255-1258.
51. Jorgensen P, Tyers M. How cells coordinate growth and division. Curr Biol 2004, 14:R1014-1027.
52. Rothermund K, Rogulski K, Fernandes E, Whiting A, Sedivy JM, Pu L, Prochownik EV. C-Myc-independent restoration of multiple phenotypes by two c-Myc target genes with overlapping functions. Cancer Res 2005, 65:2097-2107.